NCT02049866View on ClinicalTrials.gov

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 19, 2014

Primary Completion Date

March 31, 2020

Study Completion Date

December 23, 2021

Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
DRUG

Denosumab

Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months

Trial Locations (2)

10032

Columbia University Medical Center, New York

68131

Creighton University, Omaha

All Listed Sponsors
collaborator

Creighton University

OTHER

lead

Elizabeth Shane

OTHER

NCT02049866 - Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP | Biotech Hunter | Biotech Hunter